210 related articles for article (PubMed ID: 28432357)
1. In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment.
Nath O; Singh A; Singh IK
Sci Rep; 2017 Apr; 7(1):1029. PubMed ID: 28432357
[TBL] [Abstract][Full Text] [Related]
2. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
3. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
4. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
PLoS One; 2018; 13(6):e0198038. PubMed ID: 29856777
[TBL] [Abstract][Full Text] [Related]
5. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.
Sheetz JB; Mathea S; Karvonen H; Malhotra K; Chatterjee D; Niininen W; Perttilä R; Preuss F; Suresh K; Stayrook SE; Tsutsui Y; Radhakrishnan R; Ungureanu D; Knapp S; Lemmon MA
Mol Cell; 2020 Aug; 79(3):390-405.e7. PubMed ID: 32619402
[TBL] [Abstract][Full Text] [Related]
6. In Silico Approach to Identify Potential Inhibitors for Axl-Gas6 Signaling.
Peter SC; Mannu J; Mathur PP
Methods Mol Biol; 2017; 1549():221-229. PubMed ID: 27975295
[TBL] [Abstract][Full Text] [Related]
7. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
Koroleva EV; Kornoushenko YV; Karpenko AD; Bosko IP; Siniutsich JV; Ignatovich ZV; Andrianov AM
J Biomol Struct Dyn; 2023 Jun; 41(9):4065-4080. PubMed ID: 35470777
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.
Heliste J; Jokilammi A; Paatero I; Chakroborty D; Stark C; Savunen T; Laaksonen M; Elenius K
BMC Cardiovasc Disord; 2018 Oct; 18(1):196. PubMed ID: 30342492
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells.
Kamrani A; Mehdizadeh A; Ahmadi M; Aghebati-Maleki L; Yousefi M
Expert Opin Ther Targets; 2019 May; 23(5):447-456. PubMed ID: 30935250
[TBL] [Abstract][Full Text] [Related]
10.
Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
[TBL] [Abstract][Full Text] [Related]
11. An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.
Meirson T; Samson AO; Gil-Henn H
Drug Des Devel Ther; 2017; 11():1535-1557. PubMed ID: 28572720
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains.
Bainbridge TW; DeAlmeida VI; Izrael-Tomasevic A; Chalouni C; Pan B; Goldsmith J; Schoen AP; Quiñones GA; Kelly R; Lill JR; Sandoval W; Costa M; Polakis P; Arnott D; Rubinfeld B; Ernst JA
PLoS One; 2014; 9(7):e102695. PubMed ID: 25029443
[TBL] [Abstract][Full Text] [Related]
13. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
14. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
[TBL] [Abstract][Full Text] [Related]
15. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
16. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
[TBL] [Abstract][Full Text] [Related]
17. Backbone and side-chain chemical shift assignments of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1).
Ma X; Zhang Y; Liu B; Yang J; Hu K
Biomol NMR Assign; 2018 Apr; 12(1):145-148. PubMed ID: 29313214
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Handb Exp Pharmacol; 2021; 269():75-99. PubMed ID: 34490515
[TBL] [Abstract][Full Text] [Related]
19.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA).
Hijjawi MS; Abutayeh RF; Taha MO
Molecules; 2020 Dec; 25(24):. PubMed ID: 33353031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
